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Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disorder and is clinically characterized among others by memory deficits affecting first short term and then long term and spatial memory. AD constitutes a major public, medical, societal, and economic issue worldwide, with 35.6 million people suffering from the disease and a forecast of 106 million in
2050.
1 Responding effectively to this AD crisis necessitates a better understanding of this disease in order to improve diagnosis and therapy.
AD is characterized by two main types of brain lesions: (i) amyloid plaques, resulting from the extracellular accumulation of amyloid beta (Aβ) peptides; (ii) neurofibrillar degeneration, due to the intracellular aggregation of abnormally hyperphosphorylated Tau proteins. This latter aggregation is associated with an abnormal localization of Tau from the axonal compartment to the somato-dendritic compartment. 2 The discovery of mutations in the APP, PS1 and PS2 genes (coding for amyloid precursor protein, APP, and presenilins 1 and 2), responsible for early-onset, autosomal-dominant forms of AD, has placed Aβ oligomer production at the center of the pathophysiological process. 3 A better understanding of the genetic component of the common, complex forms of AD, which is exceptionally high among multifactorial aging-related diseases, 4 is required to decipher the pathophysiological processes of AD. Genome-wide association studies (GWAS) allowed for the identification of more than 30 loci associated with the late-onset forms of AD, [5] [6] [7] [8] including the bridging integrator 1 gene (BIN1). A part of these genes pointed out a potential failure in Aβ clearance, leading to more insidious Aβ accumulation in the brain. 8, 9 On the other hand, it is only recently that AD genetic risk factors have been also associated with Tau pathology, following the development of systematic screenings in Drosophila which allowed for the identification of genetic modifiers by assessing eye roughness and eye size as readouts of Tau neurotoxicity [10] [11] [12] and their associations with endophenotypes related to Tau. 10, 13, 14 Such observations are of high importance since, contrary to amyloid plaques, neurofibrillary tangles (NFTs) are well correlated with cognitive impairment both in humans 15 and in animal models. 16 Among the genes described to genetically interact with human Tau transgene in Drosophila, BIN1 was further described to directly interact with the Tau protein by NMR spectroscopy using recombinant proteins, in vitro glutathion S-transferase (GST) pull-down from HEK293
lysates, as well as reciprocal co-immunoprecipitation from mouse brain synaptosome homogenates. 17 In addition, a genome-wide significant functional risk variant in the vicinity of BIN1 locus has been associated with Tau loads (but not with Aβ loads) in AD brains. 10 The BIN1 gene codes for Amphiphysin 2, also called BIN1, a ubiquitously expressed protein involved in membrane remodeling. BIN1 comprises a N-BAR domain involved in membrane curvature sensing, an SH3 domain that binds to proline-rich motifs present in a number of proteins including itself, and a clathrin-and AP2-binding domain (CLAP) specific of the neuronal isoform 1. 18 In the central nervous system (CNS), BIN1 is mostly found in the axon initial segment, at the nodes of Ranvier, 19 and at the synapse, 20, 21 and was also associated with myelinated axons and oligodendrocytes in the white and grey matter. 22 However, little is known about its function in the CNS. We recently described the consequences of increased human BIN1 expression in the mouse brain, which exhibits early alterations in the neuronal tract between the entorhinal cortex and the dentate gyrus of the hippocampus, leading to impaired novel object recognition and aging-related changes. 21 Altogether, BIN1
overexpression affects the aging brain and induces neurodegeneration. 21 Little is also known about BIN1 in the context of AD. Several teams evaluated potential links between AD and BIN1 and determined: (i) BIN1 may regulate BACE1 intracellular trafficking through multiple mechanisms and subsequently alter Aβ peptide production; 23 (ii) BIN1 may have a role in plasma membrane remodeling during myelination, which is known to be affected in AD; 22, 24 (iii) BIN1 may participate in the neuron-to-neuron propagation of Tau prion strains; 25 and (iv) BIN1 may directly interact with Tau and interfere with Tau neurotoxicity via unknown mechanisms. 10, 26 Strong efforts are thus still needed to determine how BIN1 is involved in the pathophysiological processes of AD. In this study, we assessed for the first time the impact of human BIN1 overexpression in a mouse model of tauopathy and further dissected the interaction between Tau and BIN1 at the molecular and cellular levels using multidisciplinary approaches.
Results

BIN1 overexpression modulates hTau phenotypes in short-and long-term memory
Although a genetic interaction between Bin1 and MAPT has been shown in Drosophila and the corresponding proteins have been described to physically interact, 17 (Fig. S1 ).
To assess if BIN1 overexpression affected the short-term, non-spatial memory deficit in the hTau mice, a novel object recognition (NOR) task was performed longitudinally at 3, 6, 9, 12, and 15 months. MAPT overexpression induced short-term memory deficits in males and females from 9 months on, characterized by their inability to discriminate between familiar and novel objects (Fig. 1A) . Strikingly, hTau;TgBIN1 mice displayed short-term memory deficits earlier than hTau mice, by 3 months, both in males and females. Notably, Mapt heterozygous deletion alone had no impact on this task and TgBIN1 males present NOR deficits only starting from 6 months. 21 There was no place or object preference, regardless of genotype or sex (Fig. S2 ). In conclusion, hTau phenotypes in the NOR task appeared at an earlier age upon BIN1 overexpression.
In parallel to the NOR test, we assessed in this mouse cohort (non-naïve animals) the effect of BIN1 and MAPT overexpression on long-term spatial memory using Morris water maze (MWM) tasks at the same relative ages. All groups were able to achieve the same performance in reducing the distance needed to reach the hidden platform (Fig. 1B-E and   S3 ). The hTau mice displayed a deficit in recalling the platform location 24 h after the last training session by 12 months (Fig. 1B-E and S4 ). However, hTau;TgBIN1 males were able to perform this task at all ages tested up to 15 months, indicating that BIN1 overexpression rescued the long-term and spatial memory of the hTau mice ( Fig. 1B-E) . The hTau;TgBIN1 females displayed a delayed deficit at 15 months compared to the hTau mice (Fig. S4) .
Notably, 15-month-old TgBIN1 mice did not have a deficit in this task (Fig. S5 ). To validate that the memory deficit observed for hTau mice were not due to a visual or locomotor deficit, we measured the distance and time required by the 15 month old mice to reach the visible platform. No difference was noted in the swimming velocities of different genotypes (Fig. S6 ).
Overall, BIN1 overexpression modulates hTau phenotypes by exacerbating short-term memory deficits and preventing long-term memory deficits.
Human BIN1 expression prevents Tau intracellular inclusions and increases BIN1-Tau complexes in the hippocampus
The hTau mice have been described to develop detectable Tau aggregation and intracellular inclusions in the hippocampus and entorhinal cortex by 9 months. 27, 29 We therefore tested the hypothesis that the mechanism underlying the rescue of the long-term and spatial memory deficits in hTau males through BIN1 overexpression may be linked to an alteration of this aggregation. We sacrificed our cohort at 18 months and performed immunolabeling with antibodies specifically targeting Tau phosphorylation at both Ser202 and Thr205 (AT8 antibody) and at Thr231 (AT180 antibody) in the hippocampus (Fig. 2 ). As expected, no staining was evident in control mice. In hTau mice, Tau was mislocalized to the somatic compartment and formed prominent intracellular inclusions in the hippocampus (dentate gyrus, CA3, CA2, and CA1) ( Fig. 2A) . However, in hTau;TgBIN1 mice the number of cells with intracellular inclusions decreased by 5.9-fold or by 4.3-fold in the hippocampus when labeled with AT8 or AT180 antibodies, respectively ( Fig. 2A-C It has been previously described that BIN1 is able to physically interact with Tau. 17, 31 We assessed if BIN1 overexpression altered the amount and/or localization of BIN1-Tau complexes. For this purpose we used proximity ligation assay (PLA) in brain slices from sacrificed animals ( Fig. 2D ) and quantified the PLA density as a read-out of the BIN1-Tau interaction. We observed a strong increase in the PLA signal for the hTau;TgBIN1 mice when compared to both hTau mice and controls (2.7-fold and 6.2-fold in spot density, respectively) ( Fig. 2D-F) . As a positive control, we also used PLA to assess the interaction between α-tubulin and Tau and detected an increase in this interaction in hTau and hTau;TgBIN1 mice relative to controls (Fig. S8) . Taken together, these data indicate that BIN1 overexpression increases the amount of BIN1-Tau complexes in the hippocampus and prevents Tau mislocalization and somatic inclusion, notably in the brain regions involved in long-term and spatial memory.
BIN1 expression in neurons modulates BIN1-Tau interaction
Our data in transgenic mice support the idea that the BIN1-Tau interaction is relevant for the pathophysiological functions of Tau in AD and potentially in neurons. To gain further insight into the regulation of BIN1-Tau interaction, we monitored its dynamics during neuronal maturation in hippocampal primary neuronal cultures (PNC) at 7, 14, and 21 days in vitro (DIV), using western blots and PLA (Fig. 3) . We first observed an increase in BIN1 and Tau amounts with time ( Fig. 3A-B) , whereas Tau phosphorylation was lower at certain epitopes, in particular, at Thr231 (Fig. 3C ). Of note, this phosphorylation site has been described to inhibit the interaction between Tau's proline-rich domain (PRD) and BIN1's SH3 domains. 31 The relative density of BIN1-Tau PLA in the neuronal network was highly variable at DIV7 due to the low network density and it decreased with neuronal maturation from DIV14 to DIV21 ( Fig. 3D-E) . The BIN1-Tau PLA signal was highly correlated with the Tau signal irrespective of DIV (Fig. 3F) , suggesting a uniform distribution of PLA signals in the network.
We then assessed the impact of BIN1 expression on the PLA signal at DIV14, by downregulating BIN1 or overexpressing BIN1 neuronal isoform 1 (BIN1iso1) at DIV8 via transduction of lentiviruses expressing shRNA against BIN1 or the corresponding cDNA, respectively ( Fig. 3G-I and S9 ). BIN1 downregulation led to a decrease in PLA signal;
conversely, BIN1iso1 overexpression led to an increase in PLA signal ( Fig. 3G and 3I ).
These data indicate that even if the BIN1-Tau interaction occurred at restricted loci in neurons (e.g., at microtubule tips, as previously described 31 ), the BIN1-Tau complex formation depends on the global amount of BIN1 in neurons, as observed in the transgenic mice. Together, our data support the notion that variation in BIN1 expression affects the dynamics of BIN1-Tau complexes and their subsequent physiological and/or pathophysiological functions.
Identification of signaling pathways modulating the BIN1-Tau interaction in neurons
In addition to the BIN1 expression level as a modulator of the BIN1-Tau interaction, we had previously shown that phosphorylation of the Tau PRD domain (mainly at T231) inhibits its interaction with the BIN1 SH3 domain. 31 This suggested that BIN1-Tau interaction dynamics likely depends on specific signaling pathways that regulate Tau phosphorylation. However, the cell signaling pathways susceptible to modulate the dynamic BIN1-Tau interaction remained unknown. To answer this question, we developed an agnostic strategy and set-up a semi-automated high-content screening (HCS) approach, using PNC as cellular model and PLA volume as readout for BIN1-Tau interaction (Fig. 4A) .
We tested a library of 1,126 compounds (at 10 µM) known to mainly target key elements of canonical pathways (see the Materials and Methods section for a full description of the HCS design). In brief, HCS was made in triplicate (one well per compound in each screen) using independent cultures. 79 compounds showed potential toxicity, as assessed by Tau and MAP2 network densities (Fig. 4B) , and were excluded. We then applied several selection criteria to identify most promising compounds: (i) only compounds showing an effect in the same direction in all three independent screens were retained for further investigation; (ii) we selected the 10% of compounds showing the strongest variations (5% increasing PLA and 5% decreasing PLA). This led to 72 compounds for validation in dose-response experiments (Fig. 4C ). Following this validation step, we were able to retain 12 compounds (marked red in (iii) Ca 2+ homeostasis; (iv) membrane receptors; and (v) others (see Fig. S10 for the doseresponse curves). As BIN1-Tau interaction has been shown to be modulated by phosphorylation, 31 we decided to focus on two compounds whose targets are regulators of phosphorylation: (i) the Calcineurin (CaN) inhibitor Cyclosporin A (CsA), which, at 10 nM, increased PLA:Tau ratio by 42.6%; and (ii) the MEK inhibitor U0126, which, at 10 µM, decreased PLA:Tau ratio by 36.2% (Fig. 4E ). In conclusion, our results show that CaN and MEK-dependent signaling pathways -among others -are able to modulate the complex dynamics of the BIN1-Tau interaction in neurons.
The conformational change in BIN1 neuronal isoform 1 upon phosphorylation modulates BIN1-Tau interaction
Of particular interest, CaN is a Ser/Thr phosphatase which has been described to dephosphorylate Amphiphysin 1 (AMPH1), the homolog of BIN1. 32 We thus postulated that 5A ). Considering that AMPH1 T310 (corresponding to BIN1 T348) has been described to be phosphorylated by Cdks, 33 we hypothesized that T348 (in the vicinity of the PRD sequence interacting with the BIN1-SH3 domain 26 ) may be controlling the open/closed conformation of BIN1iso1.
We first developed an antibody against BIN1 phosphorylated at T348 to determine if the BIN1 T348 phosphorylation occurred in neurons. Treating neuronal protein extracts with a protein phosphatase pool decreased BIN1 T348 phosphorylation (Fig. 5B ). As control, Tau T231 phosphorylation was also decreased (Fig. S11A) . Next, since T348 is within a consensus sequence recognized for phosphorylation by cyclin-dependent kinases (Cdks), we tested if Cdks were able to phosphorylate BIN1 T348. By using recombinant Cdk2 or
Cdk5 and BIN1iso1, we showed that both kinases are able to directly phosphorylate T348
( Fig. 5C ), as well as Tau T231 in vitro ( Fig. S11B ) confirming previous results. 31 We finally tested CsA and U0126 in PNC for their effect on BIN1 T348 and Tau phosphorylation. We observed that CsA -but not U0126 -was able to significantly increase BIN1 T348 phosphorylation in PNC (85±26% vs. 4±26%, respectively) suggesting that CaN is indeed able to dephosphorylate BIN1 at T348 ( Fig. 5D -E). Remarkably, CaN inhibition did not impact Tau T231 phosphorylation, which we had previously described as a major modulator of the BIN1-Tau interaction, 31, 34 suggesting that the BIN1 T348 phosphorylation alone drives the impact of CsA on PLA. Conversely, U0126 likely modifies the BIN1-Tau interaction through Tau T231 phosphorylation, without any impact on BIN1 T348 ( (Fig. 6G) . Altogether, these data indicate that, in pathological conditions, the global level of the neuronal isoform of BIN1 is decreased, but a higher fraction of this BIN1 population is phosphorylated.
Discussion
There is no longer any doubt that BIN1 is a major genetic risk factor for AD. 7 However, as for other GWAS-defined genes, it is often difficult to determine the implication of such genes in pathophysiological processes (or even in physiological ones in organs of interest). In this study, we aimed to determine if the BIN1-Tau interaction is involved in the neuropathological process of a mouse tauopathy model and to decipher the cellular processes and signaling pathways potentially regulating it.
To determine if BIN1 could interfere with Tau pathology in vivo, we first developed a mammalian tauopathy model overexpressing BIN1 isoforms including neuron-specific forms in the brain. We observed that BIN1 overexpression in the hTau mice expedited the appearance of short-term memory deficits from 9 to 3 months, but prevented spatial and long-term memory deficits up to 15 months, the highest age tested. Remarkably, the rescue of spatial and long-term memory by BIN1 overexpression was associated with a strong increase in the BIN1-Tau interaction in the neuronal network and a strong decrease in phosphorylated Tau inclusions within the neuronal somata in the hippocampus. Next, we
analyzed the BIN1-Tau interaction in the physiological context. BIN1 expression level appeared to be a strong modulator of the BIN1-Tau interaction in PNC. To identify signaling pathways modulating the BIN1-Tau interaction in neurons, we developed an agnostic HCS approach and determined a number of potential targets; one of best hits being an inhibitor of CaN, a Ser/Thr phosphatase. This observation led us to identify BIN1 phosphorylation at T348 as both a CaN target and a major regulator of the BIN1-Tau interaction. We determined that BIN1 phosphorylation at T348 increased the availability of the BIN1-SH3 domain to interact with Tau and consequently led to an increase in this interaction in neurons. Finally, we determined that neuronal BIN1 isoforms (mainly isoform 1) decreased in the brains of postmortem AD patients compared to control cases, whereas -surprisingly -phospho-BIN1(T348):BIN1 ratio increased, suggesting that this site may also be involved in the AD process. Overall we hypothesize that increased BIN1 expression and its phosphorylation on T348 protects hTau mice against spatial and long-term memory deficits (Fig. 7) .
Altogether, our data support that a complex and dynamic regulation of the BIN1-Tau interaction is involved in the development of the AD pathophysiological process. However, the protective or deleterious effect of this interaction may vary depending on cognitive functions. Indeed, BIN1 overexpression modulates MAPT phenotypes by exacerbating shortterm memory deficits and by preventing long-term memory deficits. Both of these processes require the hippocampus, but the cortical regions involved are different, i.e., lateral entorhinal cortex and medial entorhinal cortex, respectively. 36, 37 The equilibrium between Tau and BIN1 levels may be slightly different in these cortical brain regions and in temporality, potentially explaining the opposite effects observed. In addition, signaling pathways controlling the phosphorylation of BIN1 and Tau, and subsequently the BIN1-Tau interaction may also differ temporally and regionally. However, since we developed a cohort study, it was not possible to evaluate such temporal and regional variations at each time of behavioral tests. It is nevertheless worth noting that the rescue of spatial and long-term memory by BIN1
overexpression was associated with a strong decrease in phosphorylated Tau inclusions within the neuronal somata and a strong increase in the BIN1-Tau interaction in the hippocampus. Remarkably, in hTau mice, the BIN1-Tau interaction was lower than in both control and htau;TgBIN1 mice. These observations thus suggest that the BIN1-Tau interaction may be protective by blocking the relocalization and accumulation of phosphorylated Tau in the neuronal somata, a major hallmark of AD.
The hypothesis that a dynamic regulation of the BIN1-Tau interaction is involved in AD process also implies that a high level of BIN1 expression would be protective. However, we previously found that total BIN1 mRNA is over-represented in the brains of AD cases compared to controls, 38 but did not evaluate at that time the isoform-dependency of the BIN1 expression. Subsequent publications reporting protein levels showed that unlike the overexpression of ubiquitous isoforms, the neuronal isoforms were specifically underexpressed in the AD brains. 39, 40 We validated this observation in brain samples and showed that this decrease was dependent on the Braak stage (Fig 6) . Since the neuronal isoforms are the main isoforms that are overexpressed in the brain of our transgenic mice model, 21 these data corroborate the idea that specific overexpression of the neuronal BIN1 isoforms may be protective. We may thus postulate that the overexpression of neuronal BIN1 isoforms in the TgBIN1 mouse reverses a neuropathological process that occurs in AD brains. This protective effect could be explained by the BIN1-Tau interaction in neurons.
However, we cannot exclude other potential mechanisms. Indeed, we observed that at 18
months MAPT over-expression is associated with myelin abnormalities, and a significant rescue of this phenotype was observed in hTau;TgBIN1 mice (Fig. S15) . Of note, the overexpression of BIN1 alone did not induce any myelin abnormalities ( Fig. S16 ; also see supplementary results). Thus, the memory impairments observed in the behavioral analyses of the hTau mice may also be associated with myelin disorganization in the fornix, and be rescued upon BIN1 overexpression. Interesting, BIN1 has been described to be strongly expressed in oligodendrocytes 22 and Tau has been also previously linked with potential myelin dysfunction in tauopathies. 41 Identifying the signaling mechanisms controlling the BIN1-Tau interaction is of high interest to understand the pathophysiological processes in AD. These pathways could be either protective or deleterious, by favoring or abrogating the BIN1-Tau interaction, respectively. In this report we characterized a key regulatory element, which is the phosphorylation of BIN1
at T348. Remarkably, we determined that the phospho-BIN1(T348):BIN1 ratio increased with increasing Braak stage in the brains of AD cases. These findings suggest that a higher fraction of brain BIN1 isoforms is phosphorylated at T348 in AD brains, where the global level of neuronal BIN1 isoforms is decreased. This may imply that the relative increase in BIN1
T348 phosphorylation occurs to compensate in part the decrease in the neuronal BIN1
isoforms in order to maintain the BIN1-Tau interaction. Altogether, these observations suggest that BIN1 T348 phosphorylation is involved in the development of AD.
Our data thus indicate that the BIN1-Tau interaction is complex and dynamic, potentially controlled by numerous actors modifying the level of phosphorylation of both BIN1 and Tau, including Cdks and CaN. Indeed, we had previously shown that the phosphorylation of Tau at T231 was a major regulator of the BIN1-Tau interaction, but in the opposite direction, i.e.,
leading to a decrease in this interaction. Importantly, the increase in Tau phosphorylation at T231 is considered as an early marker of the development of AD. 30 This dual BIN1/Tau regulation is illustrated in our HCS screening, which revealed that inhibiting CaN favors the BIN1-Tau interaction by increasing BIN T348 phosphorylation, whereas inhibiting MEK hinders it by increasing Tau T231 phosphorylation. Cdks -particularly Cdk5 -highlight this complexity, since these kinases are able to phosphorylate both BIN1 T348 and Tau T231, but with opposite effects on the abilities of Tau and BIN1 to interact with each other:
increased Cdk5 activity would increase BIN1's affinity for Tau through phosphorylation of BIN1 at T348, and, conversely, would decrease Tau's affinity for BIN1 through phosphorylating Tau at T231 (Fig. 7) . This complex interplay between actors modulating BIN1 and Tau phosphorylation may be a limitation for developing drugs to favor or prevent the BIN1-Tau interaction. A better understanding of the mechanisms involved will thus be needed to identify potential cell signaling pathways and drug targets that would uncouple the BIN1-Tau phosphorylation crosstalk. In this context, CaN-dependent pathways may be of therapeutic interest, since we observed that only BIN1 T348 is modulated by CaN, but not Tau T231.
In conclusion, we reveal the impact of overexpression of BIN1, a major genetic risk factor of AD, in a tauopathy model. Our data also reinforce the hypothesis that a potential protective impact of this overexpression on the AD process may be linked to the direct interaction of BIN1 and Tau, and depends strongly on the phosphorylation statuses of both proteins.
Materials and Methods
Animal ethics
Animal experiments were approved by the Com'Eth (project file: 2014-056) and accredited by the French Ministry for Superior Education and Research in accordance with the Directive of the European Parliament: 2010/63/EU. For all tests described, mice were kept in specific pathogen free conditions with free access to food and water, and were bred with littermates.
The light cycle was controlled as 12 h light and 12 h dark (lights on at 7AM). Before all behavioral experiments, handling was done every day for one week before the beginning of the experiment.
Mouse lines and genotyping
We used several mouse lines carrying the inactivation background. Primer sequences are available in Table S1 .
Design of behavioral experiments
Animals studied in behavioral tasks were both males and females. Same animals were longitudinally tested at 3, 6, 9, 12, and 15 months. All animals were killed at 18 months for histology and molecular biology experiments.
Novel object recognition task
This task was performed in the same conditions as in the open field paradigm (see above).
The objects to be discriminated were a glass marble (2.5 cm in diameter) and a plastic dice (2 cm). The animals were first habituated to the open field for 30 min. The next day, they were submitted to a 10 min acquisition trial during which they were placed in the open field in the presence of two similar objects (object A; marble or dice). The time the animal took to explore the object A (when the animal's snout was directed towards the object at a distance ≤ 1 cm) was recorded manually. A 10 min retention trial was performed 1 h later. During this trial, one of the familiar objects in the open field was replaced with a new one (object B), and the time periods that the animal took to explore the two objects were recorded (t A and t B for objects A and B, respectively). Two exclusion criteria were applied to select those animals that had memorized the objects: (i) during the acquisition trial, mice exploration should be longer than 3 s, and (ii) during the retention trial, mice exploration should also be longer than 3 s. The exploration index for object B was defined as (t B / (t A + t B )) × 100. Memory was defined by the percentage of time animals spent investigating the novel object statistically different from the chance (50%). To control for odor cues, the open field arena and the objects were thoroughly cleaned with 50% ethanol, dried, and ventilated between sessions.
All animals were tracked with Noldius software (Ethovision).
Morris water maze task
The Morris water maze was used to test spatial learning and memory. Each session was performed one week after NOR task and constituted the last behavioral experiment. The water maze is a circular pool (150 cm in diameter, 60 cm in height), filled with water up to 40 cm mark that is maintained at 20-22°C, and made opa que using a white aqueous emulsion Mice were left undisturbed in their home cage for 90 min intertrial intervals. On the 7 th day, mice were given the 60 s probe test, in which the platform had been removed. The distances traveled in each quadrant (NW, NE, SW, and SE) were recorded, as well as the time spent in the target quadrant. At 6, 9 and 12 months of age, the platform was located in the NE quadrant, whereas at 15 months of age, the platform was located in the SW quadrant. All animals were tracked with Noldius software (Ethovision).
Brain protein extraction and Western blotting
Mice were killed by cervical dislocation and brains were quickly removed and dissected.
Structures were immediately frozen in liquid nitrogen, and conserved at -80°C. For protein extraction we used fresh extraction buffer with pH adjusted to 7,5 (20 mM Tris at pH = 7,5; 50 mM NaCl; 2 mM EGTA; 1% Triton X-100; 10 mM NaF; 1 mM Na 3 VO 4 ; 2 mM β Glycerophosphate; cOmplete™ EDTA-free protease inhibitor cocktail). Tissues were lysed using Precellys apparatus and centrifuged at 33,000 ×g for 30 min. Protein quantification was performed using the BCA protein assay (Thermo Scientific; Waltham, MA). 10-20 µg of total protein from extracts were separated in SDS-polyacrylamide gels (10%) and transferred to nitrocellulose membranes. Depending on the target protein, we used bovine serum albumin or milk (5% in Tris-buffered saline with 0.1% Tween-20, TTBS; 1 h at RT) to block nonspecific binding sites of phosphorylated and non-phosphorylated proteins, respectively.
Immunoblotting was carried out with primary antibodies (Table S2) for 1 h at RT. Then membranes were washed 5 times in TTBS, followed by incubation with secondary antibodies conjugated with horseradish peroxidase (Table S2) . Immunoreactivity was visualized using ECL chemiluminescence system (SuperSignal™, Thermo Scientific). Chemiluminescence was captured with Amersham Imager and signals were quantified with ImageJ (NIH;
Bethesda, MD).
Immunofluorescence in brain slices
Mice were anesthetized with 5% ketamine and 10% xylazine and perfused first with PBS and then with 4% paraformaldehyde (PFA) in PBS. After removal, brains were immerged in 4%
PFA overnight at 4°C, followed by multiple rinses w ith PBS, and put in 30% sucrose in PBS until they sink. Once they sink, they were embedded in O.C.T. tissue freezing compound (Scigen; Gardena, CA), and stored at -80°C until th ey were cut with a cryostat at 10 µm thickness. For immunofluorosence, slices were first permeabilized with 0.1% Triton in PBS, with 10% horse serum and 5% BSA for 30 min. The primary antibody (Table S2 ) was then applied overnight at 4°C in the permeabilization bu ffer. After multiple rinses with PBS, the secondary antibody (Table S2) 
Electron microscopy of brain slices
Mice were PFA-fixed as described. After removal, brains were immerged in 4% PFA and 4% glutaraldehyde in PBS overnight at 4°C. Coronal sec tions were obtained with Leica VT1000
vibratome (Leica Biosystems; Nanterre, France), and the tissue was cut to expose the dorsal fornix and the upper part of the hippocampus as shown in Fig. 2 . The tissues were post-fixed in 1% osmium tetroxide, dehydrated through graded ethanol (50, 70, 90 , and 100%) and propylene oxide for 30 min each, and embedded in Epon 812 (EMS; Hatfield, PA). Semithin sections were cut at 2 µm on an ultra-microtome (Ultracut UCT; Leica) and ultrathin sections were cut at 70 nm, contrasted with uranyl acetate and lead citrate, and examined at 70 kV using a Morgagni 268D electron microscope (Thermo Scientific). Images were captured digitally by Mega View III camera (Soft Imaging System; Münster, Germany).
Primary neuronal culture
Culture media and supplements were from Thermo Scientific, unless mentioned otherwise.
Primary hippocampal neurons were obtained from P0/P1 rats, according to previously described procedures 43, 44 with minor modifications. Briefly, cortices and hippocampi were isolated from new-born rats, washed with ice-cold dissection medium (HBSS supplemented with HEPES, sodium pyruvate, and penicillin/streptomycin), and trypsinized (2.5%; 10 min; 37°C). Trypsin was inactivated with dissociation me dium (MEM supplemented with inactivated FBS, Glutamax, D-glucose (Sigma), MEM vitamins, and penicillin/streptomycin), followed by DNase (5 mg/ml; Sigma) incubation for 1 min and wash with dissection medium.
Media was replaced by dissociation medium and tissue was triturated with a fire-polished cotton-plugged Pasteur pipette to obtain a homogenous cell suspension, followed by (1:500, Thermo Fisher), mouse RZ3 Thr 231 (1:500), and mouse PHF1 phospho Ser396/404
(1:1000). The last two antibodies were kind gifts from Peter Davies. We further confirmed the specificity of this antibody for the neuronal isoform by silencing BIN1 and overexpressing BIN1iso1 or BIN1iso9 (Fig. S17) . Detection was performed using horseradish peroxidase 
Analysis of neuropathological human sample cohort
Assessment of AD-related neurofibrillary pathology (Braak stage) was performed for 14 individuals after death (Table S3 ) with immunostaining of paraffin sections with AT8 antibody, which detects hyperphosphorylated Tau. 46 Protein extractions from the frozen temporal lobe tissue samples were performed as previously described. 47 Protein quantification was performed using BCA protein assay. Total proteins (20 µg/lane) were separated on 4-12% Bis-Tris-polyacrylamide gel electrophoresis (PAGE; Invitrogen) under reducing conditions and subsequently blotted onto polyvinylidene difluoride membranes using iBlot 2 Dry Blotting System (Thermo Scientific). Primary antibodies against phospho-BIN1 Thr 348 (1:1,000), total BIN1 (1:1,000) and β-actin (1:1,000; cat. no. ab8226, Abcam) were used for immunoblotting. After incubation with the appropriate HRP-conjugated secondary antibodies, the protein bands were detected using ImageJ.
Lambda protein phosphatase assay
Crude protein extracts were incubated with Lambda protein phosphatase (New England Biolabs; Ipswich, MA), following supplier's instructions with minor changes. DIV21 PNC were harvested on ice in 40 µl ice-cold lysis buffer per well without protein phosphatase inhibitors, lysates were sonicated, centrifuged for 10 min at 1,000× g and the supernatant was distributed into 2 new tubes; volumes were adjusted to 40 µl with MilliQ H 2 O, and supplemented with 5 µl of 10× NEBuffer and 5 µl of 10 mM MnCl 2 (provided with the enzyme); 1 µl of lambda protein phosphatase (λ-PP) was added to one of the tubes and both tubes were incubated for 30 min at 30°C. 4× LDS and 10× reducing agent were added to the tubes, samples were boiled at 95°C for 10 min and i mmunoblotted as described before.
In vitro assay with recombinant proteins BIN1 phosphorylation in vitro was assessed in kinase buffer containing 20 mM MOPS, pH 7.4, 5 mM MgCl 2 , 100 µM ATP, and 1 mM DTT. Purified GST-BIN1 (500 ng) was incubated with recombinant GST-tagged Cdk5/p35 (100 ng) at RT for 1h. The reaction was terminated by the addition of boiled SDS sample buffer. After electrophoresis of the samples were run on SDS-PAGE. In addition, Cdk2/CycA3 kinase 48 was used to obtain Bin1iso1 phosphorylated on T348 residue. The capacity of the kinase to phosphorylate T348 was first verified using the CLAP (334-355) peptide as substrate and mass spectrometry to assess the addition of a phosphate group. In addition, the phosphorylated peptide was detected using the antibody directed against pT348 (Fig. S12A, inset ). For NMR experiments, 100 µM 15 NBIN1iso1 was incubated with recombinant Cdk2/CycA3 kinase (molar ratio 1/100), for 3 h at 37°C, in the presence of 2 mM ATP, 2.5 mM MgCl 2 , 2 mM EGTA, 2 mM DTT, 30 mM NaCl and protease inhibitors in 50 mM HEPES, pH 8.0 (Fig. S12) . Control experiment was performed in the absence of ATP. Phosphorylation of Bin1Iso1 at T348 was verified using western blot analysis with an antibody directed against pT348.
NMR spectroscopy
NMR experiments were recorded at 20°C on Bruker 900 -MHz spectrometer. NMR measurements were performed in 50 mM sodium phosphate buffer, pH 7. ppm, respectively, and with 48 scans. Spectra were processed using TopSpin software (Bruker). BIN1-SH3 domain backbone assignments were previously reported. 26 The NMR titration data were obtained by adding aliquots of 4 mM stock solutions of unlabeled peptides Q L R K G P P V P P P P K H T P S K E V K Q CLAP (334-355) or phospho-T348 CLAP 
Image acquisition and analysis
Coverslips were imaged with LSM 710 confocal microscope (Zeiss, Oberkochen, Germany) using a 40× 1.6 NA objective. Images were acquired at zoom 2 in z-stacks of 0.3 µm interval.
10-13 images per condition were acquired for each of the three independent experiments.
Images were deconvoluted using AutoQuantX3 Software (Bitplane, Zurich, Switzerland) and analysed with Imaris Software (Bitplane), using the "surfaces" tool for defining PLA spots, Tau network, and BIN1 puncta in three dimensions. Imaris results were analyzed using a custom MATLAB (MathWorks; Natick, MA) code that removes outliers based on ±3 median absolute deviations (MAD).
384-well plates were imaged using IN Cell Analyzer 6000 Cell Imaging System (GE Healthcare; Little Chalfont, UK) equipped with a Nikon 60× 0.95 NA objective and a CMOS camera. 16 images (2,048 × 2,048 pixels) per well were acquired in four channels (DAPI, dsRed, FITC, and Cy5) using appropriate filter sets and with following acquisition parameters: 2×2 binning; bias = 96.9; gain = 1.0 (Fig. S18 ). Images were analyzed with
Columbus image data storage and analysis system (Perkin Elmer; Waltham, MA) with analysis scripts optimized via a custom MATLAB code (Fig. S18B) . Optimal analysis scripts were determined separately for each plate.
Brain slices were imaged with Axio Scan Z1 (Zeiss) using a 40× 0.95 NA objective. Images were acquired in 12 z-stacks of 1 µm interval. Regions of interest were marked around the hippocampus during acquisition in each of the 3 independent experiments. PLA spots were analyzed with Imaris using the "surfaces" tool. Imaris results were analyzed using MATLAB after removing outliers based on ±3 MAD.
HCS script optimization and plate validation
Before 
Plate analysis and hits selection
Full plates were analyzed with optimal analysis scripts after correcting for local bias in terms of total Tau area, total MAP2 area, and total area of PLA spots within Tau area (Fig. S18C ):
First the local median of 5x5 wells surrounding the target well calculated and normalized with the plate median excluding edge wells, i.e., corrected value = raw value / (local median / plate median). For each plate, compounds affecting network quality, defined as being outside median ± 3 median absolute deviations (MAD) in terms of Tau area or Tau:MAP2 area ratio (edge wells were excluded from these calculations), were excluded (Fig. S19) . For each well, corrected PLA:Tau area ratio was normalized by plate mean, excluding edge wells and wells with compounds affecting network quality. After all screenings were performed, mean and SEM of normalized, corrected PLA:Tau area ratio were calculated for each compound, for compounds that did not affect network quality in at least 2 screenings. Compounds potentially affecting BIN1-Tau interaction were determined as those belonging to the top or bottom 5% tiers.
Validation of selected compounds
Hit validation was performed in a two-step procedure: first, dose-response curves were generated for selected compounds to identify specific effects; second, the impact of selected compounds on BIN1 phosphorylation was assessed through immunoblotting. Since several of the selected compounds had multiple protein targets at 10 µM concentration used in our screen, dose-response experiments were designed to validate the specific effects of the compounds and/or to identify relevant target proteins. Dose-response experiments were performed for 72 selected compounds that induced similar effect on PLA density in all three screens using the same protocol as for the compound screen. Selected compounds were diluted four log scales to obtain a dose-response curve (10nM, 100nM, 1µM and 10µM) and each compound and concentration was tested in three separate plates. Script optimization, plate validation, plate analysis, and well correction and exclusion processes were performed as described above. For each well, corrected PLA:Tau area ratios were normalized by the mean obtained from DMSO-treated wells of the same plate. The means of each compound at 10 µM were compared with the results from screening (conducted at 10 µM), and compounds that had similar effects in both sets of experiments were retained for further analysis. For each compound, dose-response curves were fit with 4-parameter or 3-parameter (where Hill slope is 1) nonlinear regression models, based on the extra sum-ofsquares F test using GraphPad Prism 7 (La Jolla, CA). PNC on DIV21 were incubated with selected compounds at 10 µM for 2.5 h and BIN1 and Tau phosphorylation was assessed through immunoblotting.
Statistical analysis
Statistical analyses were performed in GraphPad Prism 7 or in Matlab. When variables were normally distributed, parametric analyses were applied: one-or two-way analysis of variance (ANOVA), followed by Bonferroni-corrected post hoc tests, Student's t-test, or one sample ttest. When variables were non-normally distributed, we conducted non-parametric analysis:
Kruskal-Wallis ANOVA, followed by Dunn's test or Wilcoxon signed rank test with TukeyKramer correction. 
